Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial

Wang, ZJ; Cheng, Y; An, TT; Gao, HJ; Wang, K; Zhou, Q; Hu, YP; Song, Y; Ding, CM; Peng, F; Liang, L; Hu, Y; Huang, C; Zhou, CC; Shi, YK; Zhang, L; Ye, X; Zhang, MZ; Chuai, SK; Zhu, GS; Hu, J; Wu, YL; Wang, J

Wang, J (reprint author), Chinese Acad Med Sci, State Key Lab Mol Oncol, Dept Med Oncol, Natl Canc Ctr, Beijing 100021, Peoples R China.; Wang, J (reprint author), Chinese Acad Med Sci, Canc Hosp, Beijing 100021, Peoples R China.; Wang, J (reprint author)

LANCET RESPIRATORY MEDICINE, 2018; 6 (9): 681

Abstract

Background Detection of EGFR mutations in tumour tissue is the gold-standard approach to ascertain if a patient will benefit from treatment with an EG......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索